Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD

Respiratory Medicine

Volumn 96, Issue 10, 2002, Pages 790-795

  Cazzola, M ^a   Califano, C ^a   Di Perna, F ^a   D'amato, M ^c   Terzano, C ^d   Matera, M G ^b   D'amato, G ^a   Marsico, S A ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Department of Cardiothoracic and Respiratory Sciences   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute exacerbation of COPD; Salbutamol; Salmeterol

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUTICASONE; LEVOFLOXACIN; OXYGEN; SALBUTAMOL; SALMETEROL;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; MALE; METERED DOSE INHALER; OXYGEN SATURATION; PRIORITY JOURNAL; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL;

EID: 0036772516     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1353     Document Type: Article

References (23)

1. NHLBI/WHO. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). NHLBI/WHO Workshop Report, 2001.
2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S121.
3. Bernasconi M, Brandolese R, Poggi R, et al. Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intensive Care Med 1990; 14: 108-114.
4. Karpel JP, Pesin J, Greenberg D, et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98: 835-839.
5. Emerman CL, Cydulka RK. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1997; 29: 474-478.
6. Cazzola M, Di Perna F, D'Amato M, et al. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 2001; 95: 917-921.
7. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103-107.
8. Johnson M. The β-adrenoreceptor. Am J Respir Crit Care Med 1998; 158: S146-S153.
9. Cazzola M, Matera MG, D'Amato M, et al. Long-acting β-agonists in the treatment of mild acute exacerbations of COPD. Clin Drug Invest 2002; 22: 369-376.
10. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
11. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S-401S.
12. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl 5): S1-S28.
13. American Thoracic Society. Standardization of spirometry - 1987 update. Am Rev Respir Dis 1987; 136: 1285-1298.
14. Karpel JP, Pesin J, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98: 835-839.
15. Lloberes P, Ramis L, Montserrat JM, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988; 1: 536-539.
16. Higham MA, Sharara AM, Wilson P, Jenkins RJ, Glendenning GA. Ind PW. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma. Thorax 1997; 52: 975-980.
17. 2-agonist bronchodilators. Med Toxicol 1986; 1: 286-299.
18. Cazzola M, Di Perna F, Noschese P, et al. Effects of a pretreatment with conventional doses of formoterol, salmeterol or oxitropium bromide on the dose-response curves to salbutamol in patients suffering from partially reversible COPD. Eur Respir J 1998; 11: 1337-1341.
19. Nelson HS, Berkowitz RB, Tinkelman DA, et al. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med 1999; 159: 1556-1561.
20. 2-agonists. Is there cause for concern? Drug Saf 1997; 16: 295-308.
21. Barnes PJ. β-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152: 838-860.
22. 2-adrenoceptor agonist mediating cyclic AMP accumulation in a neuronal cell line. Br J Pharmacol 1993; 110: 619-626.
23. Wachsman DE, Kavaler JP, Sugar IP, et al. Kinetic studies of desensitization and resensitization of the relaxation response to beta-2 adrenoceptor agonists in isolated guinea pig trachea. J Pharmacol Exp Ther 1997; 280: 332-345.